Cargando…

Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers

Lung cancer survivors are at risk of developing second primary cancers (SPCs). Although some risk factors for the development of SPCs have been addressed, their impacts have not been clarified. This study, based on Taiwan’s National Health Insurance Research Database (NHIRD), a nationwide database,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Wen-Ru, Shia, Ben-Chang, Huang, Yen-Chun, Ho, Chieh-Wen, Chen, Mingchih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457496/
https://www.ncbi.nlm.nih.gov/pubmed/36079152
http://dx.doi.org/10.3390/jcm11175222
_version_ 1784786069751857152
author Chou, Wen-Ru
Shia, Ben-Chang
Huang, Yen-Chun
Ho, Chieh-Wen
Chen, Mingchih
author_facet Chou, Wen-Ru
Shia, Ben-Chang
Huang, Yen-Chun
Ho, Chieh-Wen
Chen, Mingchih
author_sort Chou, Wen-Ru
collection PubMed
description Lung cancer survivors are at risk of developing second primary cancers (SPCs). Although some risk factors for the development of SPCs have been addressed, their impacts have not been clarified. This study, based on Taiwan’s National Health Insurance Research Database (NHIRD), a nationwide database, was designed to investigate the risk factors for SPCs in patients with initial lung cancer and identify the impacts of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment on the development of SPCs. In this study, 37,954 individuals were included, of whom 2819 had SPCs. These patients were further divided into the second primary lung cancers (SPLC) and second primary extrapulmonary cancer (SPEC) groups. Among the patients with lung cancer without SPCs, those aged <65 years accounted for 53.15%. Patients aged ≥65 years accounted for 40.18% and 53.24% in the SPLC and SPEC groups, respectively. Females accounted for 50.3% of patients without SPC, 54% of the SPLC group, and 44.3% of the SPEC group. Univariate and multivariate Cox proportional hazard models showed increased hazard ratios for smoking, hypertension, and diabetes mellitus, and lower HRs for surgery, chemotherapy, radiotherapy, and TKIs. Patients undergoing surgery, chemotherapy, and radiotherapy were associated with a lower risk of SPCs. Treatment with EGFR TKIs was a significant and independent factor associated with lower incidence of SPCs. This study may encourage researchers to establish predictive models based on our results to assess the risk factors for SPCs, and therefore, early screening and intervention could be applied, and the SPCs-related mortality and relevant medical costs could be reduced.
format Online
Article
Text
id pubmed-9457496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94574962022-09-09 Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers Chou, Wen-Ru Shia, Ben-Chang Huang, Yen-Chun Ho, Chieh-Wen Chen, Mingchih J Clin Med Article Lung cancer survivors are at risk of developing second primary cancers (SPCs). Although some risk factors for the development of SPCs have been addressed, their impacts have not been clarified. This study, based on Taiwan’s National Health Insurance Research Database (NHIRD), a nationwide database, was designed to investigate the risk factors for SPCs in patients with initial lung cancer and identify the impacts of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment on the development of SPCs. In this study, 37,954 individuals were included, of whom 2819 had SPCs. These patients were further divided into the second primary lung cancers (SPLC) and second primary extrapulmonary cancer (SPEC) groups. Among the patients with lung cancer without SPCs, those aged <65 years accounted for 53.15%. Patients aged ≥65 years accounted for 40.18% and 53.24% in the SPLC and SPEC groups, respectively. Females accounted for 50.3% of patients without SPC, 54% of the SPLC group, and 44.3% of the SPEC group. Univariate and multivariate Cox proportional hazard models showed increased hazard ratios for smoking, hypertension, and diabetes mellitus, and lower HRs for surgery, chemotherapy, radiotherapy, and TKIs. Patients undergoing surgery, chemotherapy, and radiotherapy were associated with a lower risk of SPCs. Treatment with EGFR TKIs was a significant and independent factor associated with lower incidence of SPCs. This study may encourage researchers to establish predictive models based on our results to assess the risk factors for SPCs, and therefore, early screening and intervention could be applied, and the SPCs-related mortality and relevant medical costs could be reduced. MDPI 2022-09-04 /pmc/articles/PMC9457496/ /pubmed/36079152 http://dx.doi.org/10.3390/jcm11175222 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chou, Wen-Ru
Shia, Ben-Chang
Huang, Yen-Chun
Ho, Chieh-Wen
Chen, Mingchih
Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
title Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
title_full Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
title_fullStr Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
title_full_unstemmed Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
title_short Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
title_sort treating with epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) accompanying lower incidence of second primary cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457496/
https://www.ncbi.nlm.nih.gov/pubmed/36079152
http://dx.doi.org/10.3390/jcm11175222
work_keys_str_mv AT chouwenru treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers
AT shiabenchang treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers
AT huangyenchun treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers
AT hochiehwen treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers
AT chenmingchih treatingwithepidermalgrowthfactorreceptoregfrtyrosinekinaseinhibitorstkisaccompanyinglowerincidenceofsecondprimarycancers